CompletedPHASE1, PHASE2NCT05027269
Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients
Studying Proximal myotonic myopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Avidity Biosciences, Inc.
- Principal Investigator
- Li Tai, MDAvidity Biosciences, Inc.
- Intervention
- AOC 1001(drug)
- Enrollment
- 39 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2021 – 2023
Study locations (8)
- University of California Los Angeles, Los Angeles, California, United States
- Stanford University, Palo Alto, California, United States
- University of Colorado, Denver, Colorado, United States
- University of Florida, Gainesville, Florida, United States
- Kansas University Medical Center, Kansas City, Kansas, United States
- University of Rochester Medical Center, Rochester, New York, United States
- Ohio State University, Columbus, Ohio, United States
- Virginia Commonwealth University, Richmond, Virginia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05027269 on ClinicalTrials.govOther trials for Proximal myotonic myopathy
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE3NCT06549400An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.Lupin Ltd.
- RECRUITINGPHASE1, PHASE2NCT06844214A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 50 Years of Age With Non-congenital Myotonic Dystrophy Type 1Sanofi
- RECRUITINGNANCT06716931Investigating Exercise in Myotonic Dystrophy Type 2 (DM2)Massachusetts General Hospital
- RECRUITINGPHASE3NCT06523400The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2Lupin Ltd.
- RECRUITINGNCT05854433Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2Wake Forest University Health Sciences
- RECRUITINGNCT04003363The United Kingdom National Registry for Myotonic DystrophyNewcastle University
- RECRUITINGNCT02398786Myotonic Dystrophy Family RegistryMyotonic Dystrophy Foundation
- RECRUITINGNCT00082108Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy RegistryUniversity of Rochester